NovoCure
Novocure is a global oncology company pioneering a novel therapy for solid tumors. Patient images reflect patient(s) health status when photographed.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $100m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 41 % | 8 % | 1 % | (5 %) | 19 % | 5 % | 7 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 6 % | (8 %) | (17 %) | (35 %) | (18 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 4 % | (11 %) | (17 %) | (41 %) | (28 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 27 % | 38 % | 38 % | 44 % | 35 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Novocure is a global oncology company that was founded in Haifa, Israel in 2000. The company is dedicated to extending the survival of patients with some of the most aggressive forms of cancer through the development and commercialization of an innovative therapy known as Tumor Treating Fields. This therapy has shown a consistent anti-mitotic effect, which means it can stop or slow down the division of cancer cells. Novocure's therapy is being investigated in various types of cancer, including brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
Novocure's business model revolves around the development, commercialization, and provision of its Tumor Treating Fields therapy. The company primarily serves cancer patients and works closely with caregivers and advocacy partners to improve patient outcomes. Novocure also supports independent organizations with shared goals related to advancing medical care.
The company operates in the global oncology market, a sector that involves the research, development, and provision of treatments for cancer. Novocure generates revenue through the sale of its Tumor Treating Fields therapy to healthcare providers and patients. The company also invests heavily in research and development to expand the application of its therapy to other types of cancer.
Corporate social responsibility is a key aspect of Novocure's operations, with patients remaining at the heart of the work they do every day. The company is committed to redefining what it means to live with cancer and strives to improve the quality of life for patients through its innovative therapy.
Keywords: Novocure, Oncology, Tumor Treating Fields, Cancer Therapy, Glioblastoma, Mesothelioma, Brain Metastases, Gastric Cancer, Liver Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer.